Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0243026 (
sepsis
)
52,417
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cefsulodin
(
CFS
) was evaluated for its safety and efficacy in 14 children with Pseudomonas aeruginosa infections. The diagnoses included pneumonia (4),
sepsis
(1), presumed
sepsis
(4), acute postoperative ascending cholangitis (1), acute postoperative peritonitis with wandering pneumonia (1), acute enterocolitis with acute UTI (1), recurrent UTI (1), and acute cystitis (1).
CFS
was administered intravenously with a daily dose of 93 to 299 mg/kg in the cases with normal renal functions.
CFS
was effective in all but one case both clinically and bacteriologically. A case of pneumonia whose isolate was resistant to
CFS
responded poorly. Mild transient eosinophilia was observed in 3 cases, but no severe adverse reactions were encountered. Peak MIC values of 18 clinical isolates of P. aeruginosa were 1.56 mcg/ml, 0.39 to 0.78 mcg/ml and 12.5 mcg/ml for
CFS
, gentamicin, and sulbenicillin, respectively. A half life of the serum
CFS
levels was 1.09 hours after intravenous bolus injection of 20 to 25 mg/kg of
CFS
(n = 2). A cerebrospinal-fluid level and biliary levels measured in cases with inflamed meninges or with cholangitis were well above the MIC value. From the present study,
CFS
appeared to be a safe and effective antibiotic when used in children with susceptible Pseudomonas infections. Combined use of another antibiotic should be considered in the case with polymicrobial infections because of the
CFS
's very narrow spectrum.
...
PMID:[Clinical evaluation of cefsulodin in Pseudomonas infections in children]. 716 64